Journal of Clinical Immunology and Allergy

Therapeutic use of microRNAs in different types of immune diseases

15 ^th International Conference on Immunology
July 05- 07 , 2018 Vienna , Austria

Gilbert Glady

European Bio Immune(G)ene Medicine Association, France

Keynote: Insights Allergy Asthma Bronchitis

DOI: 10.21767/2471-304X-C1-001

Abstract

MicroRNAs (miRNAs) constitute a biologically very important class of small, noncoding RNAs, about 18–22 nucleotides (nt) long, that mainly act as negative regulators of gene expression at posttranscriptional level by controlling the translation and stability of mRNA target. It is known that a miRNA may target several mRNAs as well as the mRNA that can be under the control of several miRNAs. The dysregulation of miRNAs has been frequently observed in different types of disease, including cancer, autoimmune driven diseases, many allergies, metabolic pathologies. All these data make it possible to identify microRNAs as almost ideal targets for human therapeutics. In spite of numerous attempts in this direction, many therapeutic trials have finally failed due to methodological difficulties sometimes, but mainly because of insurmountable adverse effects. In recent years, we have developed a nanotherapy using ultra-low doses of microRNAs (concentrations are of the order of the nanogram) administered sub-lingually, which we called Bio Immune(G)ene Medicine, and which allows to use microRNAs for therapeutic purposes without particular difficulty. A number of clinical examples should illustrate the methodology used and highlight the therapeutic efficacy of this highly innovative new medical approach of multiple chronic diseases.

Biography

Gilbert Glady Born in Strasbourg, France, Dr. Gilbert Glady graduated from Medical School in 1977 and was then an intern in onco-hematology at the university clinic for several years. After a specialization in homeopathy and naturopathy in Paris, he returned to the Alsace region to work as a private practitioner. Through his work and encounters, he developed interest and expertise in immunology and immunogenetics, that leaded him to nanomedicine and nanobiotechnology. He thus became in 2010 the creator of the BI(G)MED method (Bio Immune (G)ene Medicine) and director of EBMA, the European association responsible for communication and trainings in the field of BI(G) MED. He has participated in numerous international congresses in immuno-allergology, infectiology and oncology with posters and oral presentations, and is the author of several publications on nanobiotherapy in different journals.

E-mail: info@ebma-europe.com